Camilo Rojas

Camilo Rojas

Auto-generated profile, based on publicly available information

Camilo Rojas

Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in European Journal of Pharmacology
Verified
Journal Article
Closed access
CRCamilo Rojas
Camilo Rojas
ATAjit G. Thomas
Ajit G. Thomas
JAJesse Alt
Jesse Alt
MSMarigo Stathis
Marigo Stathis
JZJie Zhang
Jie Zhang
BSBarbara S. Slusher
Barbara S. Slusher

1 January 2014 in European Journal of Pharmacology
Verified
Journal Article
Closed access
CRCamilo Rojas
Camilo Rojas
MRMithun Raje
Mithun Raje
TTTakashi Tsukamoto
Takashi Tsukamoto
BSBarbara S. Slusher
Barbara S. Slusher

26 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MFMariana Figuera-Losada
Mariana Figuera-Losada
MSMarigo Stathis
Marigo Stathis
JDJoelle M. Dorskind
Joelle M. Dorskind
ATAjit G. Thomas
Ajit G. Thomas
VBVeera Venkata Ratnam Bandaru
Veera Venkata Ratnam Bandaru
CRCamilo Rojas
Camilo Rojas
Ceramide is a bioactive lipid that plays an important role in stress responses leading to apoptosis, cell growth arrest and differentiation. Ceramide production is due in part to sphingomyelin hydrolysis by sphingomyelinases. In brain, neutral sphingomyelinase 2 (nSMase2) is expressed in neurons and increases in its activity and expression have been associated with pro-inflammatory conditions observed in Alzheimer’s disease, multiple sclerosis and human immunodeficiency virus (HIV-1) patients. Increased nSMase2 activity translates into higher ceramide levels and neuronal cell death, which can be prevented by chemical or genetic inhibition of nSMase2 activity or expression. However, to date, there are no soluble, specific and potent small molecule inhibitor tool compounds for in vivo studies or as a starting point for medicinal chemistry optimization. Moreover, the majority of the known inhibitors were identified using bacterial, bovine or rat nSMase2. In an attempt to identify new inhibitor scaffolds, two activity assays were optimized as screening platform using the recombinant human enzyme. First, active hits were identified using a fluorescence-based high throughput compatible assay. Then, hits were confirmed using a 14C sphingomyelin-based direct activity assay. Pharmacologically active compounds and approved drugs were screened using this strategy which led to the identification of cambinol as a novel uncompetitive nSMase2 inhibitor (Ki = 7 μM). The inhibitory activity of cambinol for nSMase2 was approximately 10-fold more potent than for its previously known target, silence information regulator 1 and 2 (SIRT1/2). Cambinol decreased tumor necrosis factor-α or interleukin-1 β-induced increases of ceramide and cell death in primary neurons. A preliminary study of cambinol structure and activity allowed the identification of the main structural features required for nSMase2 inhibition. Cambinol and its analogs may be useful as nSMase2 inhibitor tool compounds to prevent ceramide-dependent neurodegeneration.

7 December 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRCamilo Rojas
Camilo Rojas
EBElena Barnaeva
Elena Barnaeva
ATAjit G. Thomas
Ajit G. Thomas
XHXin Hu
Xin Hu
NSNoel Southall
Noel Southall
BSBarbara S. Slusher
Barbara S. Slusher
Brain injury and inflammation induces a local release of extracellular vesicles (EVs) from astrocytes carrying proteins, RNAs, and microRNAs into the circulation. When these vesicles reach the liver, they stimulate the secretion of cytokines that mobilize peripheral immune cell infiltration into the brain, which can cause secondary tissue damage and impair recovery. Recent studies suggest that suppression of EV biosynthesis through neutral sphingomyelinase 2 (nSMase2) inhibition may represent a new therapeutic strategy. Unfortunately, currently available nSMase2 inhibitors exhibit low potency (IC50 ≥ 1 μM), poor solubility and/or limited brain penetration. Through a high throughput screening campaign of >365,000 compounds against human nSMase2 we identified 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP), a potent (IC50 30 nM), selective, metabolically stable, and brain penetrable (AUCbrain/AUCplasma = 0.26) nSMase2 inhibitor. DPTIP dose-dependently inhibited EV release in primary astrocyte cultures. In a mouse model of brain injury conducted in GFAP-GFP mice, DPTIP potently (10 mg/kg IP) inhibited IL-1β-induced astrocyte-derived EV release (51 ± 13%; p < 0.001). This inhibition led to a reduction of cytokine upregulation in liver and attenuation of the infiltration of immune cells into the brain (80 ± 23%; p < 0.01). A structurally similar but inactive analog had no effect in vitro or in vivo.

13 August 2018 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
XZXiaolei Zhu
Xiaolei Zhu
MNMichael T. Nedelcovych
Michael T. Nedelcovych
ATAjit G. Thomas
Ajit G. Thomas
YHYuto Hasegawa
Yuto Hasegawa
AMAisa Moreno-Megui
Aisa Moreno-Megui
AKAtsushi Kamiya
Atsushi Kamiya
There are a number of clinically effective treatments for stress-associated psychiatric diseases, including major depressive disorder (MDD). Nonetheless, many patients exhibit resistance to first-line interventions calling for novel interventions based on pathological mechanisms. Accumulating evidence implicates altered glutamate signaling in MDD pathophysiology, suggesting that modulation of glutamate signaling cascades may offer novel therapeutic potential. Here we report that JHU-083, our recently developed prodrug of the glutaminase inhibitor 6-diazo-5-oxo-l-norleucine (DON) ameliorates social avoidance and anhedonia-like behaviors in mice subjected to chronic social defeat stress (CSDS). JHU-083 normalized CSDS-induced increases in glutaminase activity specifically in microglia-enriched CD11b+ cells isolated from the prefrontal cortex and hippocampus. JHU-083 treatment also reverses the CSDS-induced inflammatory activation of CD11b+ cells. These results support the importance of altered glutamate signaling in the behavioral abnormalities observed in the CSDS model, and identify glutaminase in microglia-enriched CD11b+ cells as a pharmacotherapeutic target implicated in the pathophysiology of stress-associated psychiatric conditions such as MDD.

4 August 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
RRRana Rais
Rana Rais
WJWeiwei Jiang
Weiwei Jiang
HZHui-hong Zhai
Hui-hong Zhai
KWKrystyna M. Wozniak
Krystyna M. Wozniak
MSMarigo Stathis
Marigo Stathis
BSBarbara S. Slusher
Barbara S. Slusher
Recent gene-profiling analyses showed significant upregulation of the folate hydrolase ( FOLH1 ) gene in the affected intestinal mucosa of patients with inflammatory bowel disease (IBD). The FOLH1 gene encodes a type II transmembrane glycoprotein termed glutamate carboxypeptidase II (GCPII). To establish that the previously reported increased gene expression was functional, we quantified the glutamate carboxypeptidase enzymatic activity in 31 surgical specimens and report a robust 2.8- to 41-fold increase in enzymatic activity in the affected intestinal mucosa of IBD patients compared with an uninvolved area in the same patients or intestinal mucosa from healthy controls. Using a human-to-mouse approach, we next showed a similar enzymatic increase in two well-validated IBD murine models and evaluated the therapeutic effect of the potent FOLH1 /GCPII inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA) (IC 50 = 300 pM). In the dextran sodium sulfate (DSS) colitis model, 2-PMPA inhibited the GCPII activity in the colonic mucosa by over 90% and substantially reduced the disease activity. The significance of the target was confirmed in FOLH1 –/– mice who exhibited resistance to DSS treatment. In the murine IL-10 –/– model of spontaneous colitis, daily 2-PMPA treatment also significantly reduced both macroscopic and microscopic disease severity. These results provide the first evidence of FOLH1 /GCPII enzymatic inhibition as a therapeutic option for IBD.